BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1747371)

  • 21. Characterization of murine anti-glycoprotein Ib monoclonal antibodies that differentiate between shear-induced and ristocetin/botrocetin-induced glycoprotein Ib-von Willebrand factor interaction.
    Cauwenberghs N; Ajzenberg N; Vauterin S; Hoylaerts MF; Declerck PJ; Baruch D; Deckmyn H
    Haemostasis; 2000; 30(3):139-48. PubMed ID: 11014964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of Crotalus atrox.
    Chang MC; Lin HK; Peng HC; Huang TF
    Blood; 1998 Mar; 91(5):1582-9. PubMed ID: 9473223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crotalin, a vWF and GP Ib cleaving metalloproteinase from venom of Crotalus atrox.
    Wu WB; Peng HC; Huang TF
    Thromb Haemost; 2001 Dec; 86(6):1501-11. PubMed ID: 11776320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding site on human von Willebrand factor of bitiscetin, a snake venom-derived platelet aggregation inducer.
    Matsui T; Hamako J; Matsushita T; Nakayama T; Fujimura Y; Titani K
    Biochemistry; 2002 Jun; 41(25):7939-46. PubMed ID: 12069583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura.
    Moore JC; Murphy WG; Kelton JG
    Br J Haematol; 1990 Apr; 74(4):457-64. PubMed ID: 2346725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of von Willebrand factor-induced platelet agglutination by ADP does not result from reduced binding of total von Willebrand factor or its larger multimers.
    Zucker MB; Puszkin EG; Sussman II; Mauss EA
    J Lab Clin Med; 1990 Sep; 116(3):305-14. PubMed ID: 2401846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors.
    De Marco L; Mazzuccato M; Grazia Del Ben M; Budde U; Federici AB; Girolami A; Ruggeri ZM
    J Clin Invest; 1987 Aug; 80(2):475-82. PubMed ID: 3038958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aurin tricarboxylic acid inhibits platelet adhesion to collagen by binding to the 509-695 disulphide loop of von Willebrand factor and competing with glycoprotein Ib.
    Girma JP; Fressinaud E; Christophe O; Rouault C; Obert B; Takahashi Y; Meyer D
    Thromb Haemost; 1992 Dec; 68(6):707-13. PubMed ID: 1287886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct abnormalities in the interaction of purified types IIA and IIB von Willebrand factor with the two platelet binding sites, glycoprotein complexes Ib-IX and IIb-IIIa.
    De Marco L; Mazzucato M; De Roia D; Casonato A; Federici AB; Girolami A; Ruggeri ZM
    J Clin Invest; 1990 Sep; 86(3):785-92. PubMed ID: 2394830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin.
    Berndt MC; Ward CM; Booth WJ; Castaldi PA; Mazurov AV; Andrews RK
    Biochemistry; 1992 Nov; 31(45):11144-51. PubMed ID: 1359905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ristocetin-dependent reconstitution of binding of von Willebrand factor to purified human platelet membrane glycoprotein Ib-IX complex.
    Berndt MC; Du XP; Booth WJ
    Biochemistry; 1988 Jan; 27(2):633-40. PubMed ID: 2450575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-linking of a monomeric 39/34-kDa dispase fragment of von Willebrand factor (Leu-480/Val-481-Gly-718) to the N-terminal region of the alpha-chain of membrane glycoprotein Ib on intact platelets with bis(sulfosuccinimidyl) suberate.
    Andrews RK; Gorman JJ; Booth WJ; Corino GL; Castaldi PA; Berndt MC
    Biochemistry; 1989 Oct; 28(21):8326-36. PubMed ID: 2690940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential aspects of the glycoprotein Ib-von Willebrand factor axis in human and pig species.
    Zurbano MJ; Escolar G; Heras M; Ordinas A; Castillo R
    Haematologica; 2000 May; 85(5):514-9. PubMed ID: 10800169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein IB- and IIB/IIIA-binding domains.
    Tornai I; Arnout J; Deckmyn H; Peerlinck K; Vermylen J
    J Clin Invest; 1993 Jan; 91(1):273-82. PubMed ID: 8423224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional modulation of the isolated glycoprotein Ib binding domain of von Willebrand factor expressed in Escherichia coli.
    Sugimoto M; Ricca G; Hrinda ME; Schreiber AB; Searfoss GH; Bottini E; Ruggeri ZM
    Biochemistry; 1991 May; 30(21):5202-9. PubMed ID: 2036386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular cloning and characterization of a platelet glycoprotein Ib-binding protein from the venom of Trimeresurus stejnegeri.
    Lee WH; Zhang Y
    Toxicon; 2003 Jun; 41(7):885-92. PubMed ID: 12782089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High shear stress attenuates agonist-induced, glycoprotein IIb/IIIa-mediated platelet aggregation when von Willebrand factor binding to glycoprotein Ib/IX is blocked.
    Iijima K; Murata M; Nakamura K; Kitaguchi T; Handa M; Watanabe K; Fujimura Y; Yoshioka A; Ikeda Y
    Biochem Biophys Res Commun; 1997 Apr; 233(3):796-800. PubMed ID: 9168936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha-thrombin.
    Ward CM; Andrews RK; Smith AI; Berndt MC
    Biochemistry; 1996 Apr; 35(15):4929-38. PubMed ID: 8664285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.
    Rabinowitz I; Tuley EA; Mancuso DJ; Randi AM; Firkin BG; Howard MA; Sadler JE
    Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9846-9. PubMed ID: 1409710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiplatelet glycoprotein Ib monoclonal antibody (OP-F1) totally abolishes ristocetin-induced von Willebrand factor binding, but has minimal effect on the botrocetin-induced binding.
    Nishio K; Fujimura Y; Nishida S; Takeda I; Yoshioka A; Fukui H; Tomiyama Y; Kurata Y
    Haemostasis; 1991; 21(6):353-9. PubMed ID: 1823880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.